Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Curium's Bexlutry (lutetium Lu 177 dotatate), first radioligand equivalent targeting somatostatin receptor for gastroenteropancreatic neuroendocrine tumors
Radioligand therapy, cancer, neuroendocrine tumors, somatostatin receptor, generic drug - Read more

NICE backs Johnson & Johnson's daratumumab quadruplet as first-line therapy for transplant-eligible myeloma patients
Monoclonal antibody, oncology, regulatory, financial - Read more

Eli Lilly, QurCan Therapeutics collaborate on CNS genetic medicine delivery, up to $237M milestones per program
Research collaboration, neurological, gene therapy, drug delivery, milestone payments - Read more

Sanofi divests 20 mature medicines, three manufacturing sites to Cheplapharm for 26.4% equity stake
Divestiture, manufacturing agreement, equity investment, R&D, small molecule - Read more

GSK acquires Chimagen Biosciences' trispecific T cell engager for multiple myeloma, deal worth up to $750M
Licensing deal, oncology, antibody, multiple myeloma, milestone payments - Read more

Aptar Pharma, Massachusetts General Hospital collaborate on translational platform to advance nose-to-brain drug delivery
Research collaboration, drug delivery, neurological, computational modeling, small molecule - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Corbus Pharmaceuticals posts Ph1b data for (CRB-913) targeting cannabinoid receptor 1 inverse agonism in obesity
Small molecule, metabolic, CB1 inverse agonist, obesity, neuropsychiatric safety - Read more

CSL Seqirus publishes Ph3 data for AUJEMFLU (MF59-adjuvanted cell-based quadrivalent influenza vaccine) showing superiority in older adults
Vaccine, infectious disease, influenza, older adults, adjuvanted vaccine - Read more

Vera Therapeutics' Trutakna (atacicept-vymj) Ph3 data support full FDA approval bid for IgA nephropathy
Protein therapy, autoimmune, fusion protein, IgA nephropathy, BAFF and APRIL inhibition, kidney disease - Read more

ANGELIS Oncology launches, acquires PLX038 from ProLynx, and initiates glioblastoma clinical trial
Small molecule prodrug, oncology, strategic, major transaction - Read more

One04 Therapeutics launches as clinical-stage company on encouraging CPV-104 Phase 1 results, expanding to kidney disease and dry AMD
Recombinant protein, rare disease, complement-mediated disease, ophthalmology, strategic - Read more

Electra Therapeutics plans $325M IPO to fund late-stage sHLH trial
Rare disease, antibody, autoimmune, clinical-stage - Read more

QL Biopharmaceutical raises ~CNY 300M ($44.7M) Series C+, advancing once-monthly GLP-1 receptor agonist zovaglutide
Metabolic disease, GLP-1 receptor agonist, peptide, clinical-stage - Read more

VERDOT opens new Centre of Excellence in France, boosting manufacturing capacity by 150%
Bioprocessing equipment, biopharmaceutical manufacturing, operational, capacity expansion - Read more

FDA launches Operation TrialBlazer, accepting applications to accelerate early-phase U.S. clinical trials
IND program, drug development, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novo terminates Ascendis GLP-1 obesity drug pact worth up to $285M after under two years
Licensing deal, metabolic disease, small molecule, GLP-1, milestone payments, royalties - Read more

Axoltis Pharma's NX210c (NX210c) misses Ph2 primary endpoint in amyotrophic lateral sclerosis but secondary data support continuation
Protein therapy, neurological, synthetic peptide, ALS, blood-brain barrier - Read more

Eli Lilly terminates Ph1 trial of experimental obesity drug LY4064912 after failing to meet internal development standards
Protein therapy, metabolic, obesity, GLP-1 receptor agonist, phase 1 trial - Read more

J&J, Contineum Therapeutics' (JNJ-5120) M1 receptor antagonist fails Ph2 for major depressive disorder
Small molecule, neurological, M1 receptor antagonist, major depressive disorder, multiple sclerosis - Read more

Connect Biopharma's (rademikibart) misses primary endpoint in Ph2 asthma trial targeting IL-4/IL-13
Antibody, autoimmune, monoclonal antibody, asthma, IL-4/IL-13 blockade, atopic dermatitis - Read more

Sionna Therapeutics lays off 46% of workforce after cystic fibrosis trial failure, pivots to phase 2 study
Small molecule, cystic fibrosis, strategic, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here